Colin Heitzmann

Colin Heitzmann has extensive experience in the field of pharmaceutical intellectual property and FDA matters. Colin began their career as a Registered Patent Attorney at Finnegan, Henderson, Farabow, Garrett & Dunner LLP in 2002, focusing on pharmaceutical and chemical intellectual property matters. Colin then joined Winston & Strawn LLP in 2007, where they continued to specialize in pharmaceutical intellectual property and FDA matters. In 2011, Heitzmann became a Registered Patent Attorney at Sterne, Kessler, Goldstein & Fox PLLC, where they focused their practice on pharmaceutical intellectual property and FDA matters, including patent litigation, regulatory counseling, and transactional matters. Colin later joined Otsuka Pharmaceutical Companies (U.S.) in 2013 as a Corporate Attorney and eventually became the Head of US IP Group and Senior Director for Intellectual Property Counsel. In 2021, Heitzmann joined Sumitovant Biopharma, Inc. as the Vice President and Head of Intellectual Property. Currently, they hold the position of Vice President of Intellectual Property and Business Development at Daiichi Sankyo, Inc.

Colin Heitzmann earned a Juris Doctor (J.D.) degree in Law from the University of Michigan Law School from 1999 to 2002. Prior to that, they pursued a Master of Science in Engineering (M.S.E.) in Environmental Engineering with a concentration in chemistry at the University of Michigan from 1997 to 1999. Colin also completed their undergraduate studies in Geo-Environmental Engineering at Penn State University, specifically at the Schreyer Honors College, before 1997.